纳武利尤单抗对比研究者选择的标准单药治疗复发或转移性头颈部鳞状细胞癌(CheckMate 141):一项随机3期试验的健康相关生活质量结果
CheckMate 141 是一项随机、开放标签、3期试验,纳入铂类难治性复发或转移性头颈部鳞状细胞癌患者,随机接受纳武利尤单抗(n=240)或研究者选择单药(n=121)。探索性分析显示,纳武利尤单抗组从基线至第15周症状和功能稳定,而研究者选择组在多个领域出现临床意义恶化;纳武利尤单抗组至恶化时间显著延长。
要点
- 纳武利尤单抗组从基线至第15周EORTC QLQ-C30各功能及症状领域调整后平均变化为-2.1至5.4,无领域显示临床意义恶化。
- 研究者选择组15个领域中有8个(53%)在第15周出现临床意义恶化(≥10分),变化范围为-24.5至2.4。
- 纳武利尤单抗组在35个评估领域中有13个(37%)至恶化时间显著长于研究者选择组。
核心结论
- 纳武利尤单抗从基线至第9周和第15周稳定症状和功能,而研究者选择导致临床意义恶化。
- 与研究者选择的单药治疗相比,纳武利尤单抗延迟了铂类难治性复发或转移性头颈部鳞状细胞癌患者报告的生活质量结局的恶化时间。
- 鉴于该人群存在重大未满足需求以及维持或改善生活质量的重要性,这些数据支持纳武利尤单抗作为该 setting 的新标准治疗选择。
研究设计与样本
- CheckMate 141 是一项随机、开放标签、3期试验,纳入铂类化疗后6个月内进展的复发或转移性头颈部鳞状细胞癌患者。
- 患者按2:1随机分配至纳武利尤单抗3 mg/kg每2周(n=240)或研究者选择(n=121)甲氨蝶呤(40-60 mg/m2体表面积)、多西他赛(30-40 mg/m2)或西妥昔单抗(负荷剂量400 mg/m2后250 mg/m2)。
- 患者于2014年5月29日至2015年7月31日入组,共361例随机分配。
- 在基线和至少一次其他评估中完成任何PRO问卷的患者共129例(纳武利尤单抗组93例,研究者选择组36例)。
- PROs作为探索性终点,在基线、第9周及此后每6周使用EORTC QLQ-C30、EORTC QLQ-H&N35和EQ-5D三水平问卷评估。
主要发现
- 纳武利尤单抗组从基线至第15周EORTC QLQ-C30功能及症状领域调整后平均变化范围为-2.1至5.4,无领域显示临床意义恶化。
- 研究者选择组15个领域中有8个(53%)在第15周显示临床意义恶化(10分或以上),变化范围为-24.5至2.4。
- EORTC QLQ-H&N35第15周临床意义恶化:纳武利尤单抗组无领域,研究者选择组18个领域中有8个(44%)。
- EQ-5D视觉模拟量表从基线至第15周调整后平均变化:纳武利尤单抗组7.3(临床意义改善,差异≥7分)vs 研究者选择组-7.8(临床意义恶化)。
- 第9周和第15周组间差异显著且有临床意义,有利于纳武利尤单抗的领域包括EORTC QLQ-C30的角色功能、社会功能、疲劳、呼吸困难、食欲丧失,以及EORTC QLQ-H&N35的疼痛和感觉问题。
关键数值与推荐
- EORTC QLQ-C30临床意义恶化阈值定义为10分或以上。
- EQ-5D视觉模拟量表临床意义改善定义为差异7分或以上。
- 纳武利尤单抗剂量为3 mg/kg每2周;甲氨蝶呤40-60 mg/m2体表面积;多西他赛30-40 mg/m2;西妥昔单抗负荷剂量400 mg/m2后250 mg/m2。
临床怎么用
- 原文结论指出,这些数据支持纳武利尤单抗作为铂类难治性复发或转移性头颈部鳞状细胞癌的新标准治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patient-reported outcomes (PROs). METHODS: CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who progressed within 6 months after platinum-based chemotherapy. Patients were randomly assigned (2:1) to nivolumab 3 mg/kg every 2 weeks (n=240) or investigator's choice (n=121) of methotrexate (40-60 mg/m2 of body surface area), docetaxel (30-40 mg/m2), or cetuximab (250 mg/m2 after a loading dose of 400 mg/m2) until disease progression, intolerable toxicity, or withdrawal of consent. On Jan 26, 2016, the independent data monitoring committee reviewed the data at the planned interim analysis and declared overall survival superiority for nivolumab over investigator's choice therapy (primary endpoint; described previously). The protocol was amended to allow patients in the investigator's choice group to cross over to nivolumab. All patients not on active therapy are being followed for survival. As an exploratory endpoint, PROs were assessed at baseline, week 9, and every 6 weeks thereafter using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), the EORTC head and neck cancer-specific module (EORTC QLQ-H&N35), and the three-level European Quality of Life-5 Dimensions (EQ-5D) questionnaire. Differences within and between treatment groups in PROs were analysed by ANCOVA among patients with baseline and at least one other assessment. All randomised patients were included in the time to clinically meaningful deterioration analyses. Median time to clinically meaningful deterioration was analysed by Kaplan-Meier methods. CheckMate 141 was registered with ClinicalTrials.org, number NCT02105636. FINDINGS: Patients were enrolled between May 29, 2014, and July 31, 2015, and subsequently 361 patients were randomly assigned to receive nivolumab (n=240) or investigator's choice (n=121). Among them, 129 patients (93 in the nivolumab group and 36 in the investigator's choice group) completed any of the PRO questionnaires at baseline and at least one other assessment. Treatment with nivolumab resulted in adjusted mean changes from baseline to week 15 ranging from -2·1 to 5·4 across functional and symptom domains measured by the EORTC QLQ-C30, with no domains indicating clinically meaningful deterioration. By contrast, eight (53%) of the 15 domains in the investigator's choice group showed clinically meaningful deterioration (10 points or more) at week 15 (change from baseline range, -24·5 to 2·4). Similarly, on the EORTC QLQ-H&N35, clinically meaningful worsening at week 15 was seen in no domains in the nivolumab group and eight (44%) of 18 domains in the investigator's choice group. Patients in the nivolumab group had a clinically meaningful improvement (according to a difference of 7 points or greater) in adjusted mean change from baseline to week 15 on the EQ-5D visual analogue scale, in contrast to a clinically meaningful deterioration in the investigator's choice group (7·3 vs -7·8). Differences between groups were significant and clinically meaningful at weeks 9 and 15 in favour of nivolumab for role functioning, social functioning, fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C30 and pain and sensory problems on the EORTC QLQ-H&N35. Median time to deterioration was significantly longer with nivolumab versus investigator's choice for 13 (37%) of 35 domains assessed across the three questionnaires. INTERPRETATION: In this exploratory analysis of CheckMate 141, nivolumab stabilised symptoms and functioning from baseline to weeks 9 and 15, whereas investigator's choice led to clinically meaningful deterioration. Nivolumab delayed time to deterioration of patient-reported quality-of-life outcomes compared with single-agent therapy of investigator's choice in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck. In view of the major unmet need in this population and the importance of maintaining or improving quality of life for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data support nivolumab as a new standard-of-care option in this setting. FUNDING: Bristol-Myers Squibb.
引用
- Harrington KJ, Ferris RL, Blumenschein G, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 28651929. doi:10.1016/S1470-2045(17)30421-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。